In the quest to foster innovation in America’s most critical sectors – from life-saving biotech and clean energy to infrastructure and cutting-edge tech – entrepreneurs face well-known hurdles like technical challenges and market competition. But there’s another, largely invisible headwind that Wall Street rarely discusses abusive short selling. Particularly insidious is naked short selling, an illegal practice where shares are sold short without being borrowed, effectively conjuring phantom stock that can flood the market. This creates an unseen drag on share prices, eroding companies’ valuations and, in turn, their ability to fund innovative projects. Prominent investigators estimate that over 1,000 public companies have more shares trading than they ever issued, indicating pervasive naked shorting that leaves many firms “susceptible to artificial deflation of their share price”. In other words, investors might unknowingly be holding shares “that do not exist”. Such artificial selling pressure doesn’t just hurt stock prices – it can strangle the finances and morale of ventures working on groundbreaking cures, clean technologies, or infrastructure improvements.
What Is Abusive Short Selling?
To be clear, short selling itself is a legal market mechanism: an investor borrows shares and sells them, hoping to buy back later at a lower price and pocket the difference. Abusive short selling goes beyond the norm – using tactics like naked shorting or spreading false information (the “short-and-distort” scheme) to drive prices down. In naked shorting, because the short seller never actually borrows the shares, trades fail to deliver, and the supply of tradable shares is artificially inflated. A Wall Street lawyer fighting these cases noted that naked shorting “virtually impacts every business sector on every exchange”, even hitting many billion-dollar NYSE companies. His research suggested at least 500 companies have more shares in circulation than their entire outstanding issuance – a sign that aggressive short sellers have diluted the equity with phantom shares, crushing the stock price in the process. This practice is supposed to be barred by SEC rules, but enforcement loopholes have allowed bad actors to exploit technical backdoors in the trading and clearing system. The result is a fraudulent over-supply of shares that can drive a company’s valuation down regardless of its performance.
Equally damaging is the “short and distort” tactic whereby shorts short sell a stock and then spread false or misleading negative reports to panic other investors. The SEC has charged hedge fund operators for doing exactly this, for example, one adviser shorted a biotech stock and then issued bogus claims that the company was near bankruptcy, causing the stock to lose one-third of its value. Regulators made clear: while short sellers are free to voice opinions, they cannot bolster those opinions with false statements. Unfortunately, in practice many such attacks fly under the radar, and their cumulative effect is an erosion of trust in the market for innovative companies.
Eroding Investor Trust and Funding
For startups and R&D-heavy firms, the stock price isn’t just a number, it’s their lifeline to raise growth capital. When abusive short selling schemes batter a stock, investor confidence evaporates and new funding can dry up overnight. CEOs describe it as watching their company’s stock become a pawn in someone else’s profit game. As one report noted, executives fear that short sellers “manipulate the market for profit,” and with modern trading algorithms scanning social media, a flurry of false rumors can unfairly shift market momentum against a company. Negative news, even unsubstantiated, spreads faster than ever, triggering knee-jerk selloffs. This loss of confidence makes investors hesitant to put money into the next biotech cure or clean energy venture if they believe powerful hedge funds can torpedo the stock at will. It’s hard to invest in innovation when you suspect the game is rigged.
Even worse, a company under a short attack may be forced to raise capital at a much lower share price than it deserves, diluting existing shareholders and yielding far less funding for the business. A recent case in point: Northwest Biotherapeutics (NWBO), a small biotech developing a promising brain cancer vaccine, saw years of encouraging trial results fail to translate into stock growth. Why? NWBO alleges that a cartel of market-makers engaged in waves of spoofing and naked short selling to hold its price down. Despite reporting positive Phase 3 results for its immunotherapy, NWBO’s share price “did not follow suit” – instead it dropped sharply due to manipulation, according to the company’s ongoing lawsuit. The consequences were severe: NWBO had to sell over 274 million shares at artificially depressed prices to fund operations, incurring massive dilution and depriving itself of capital it could have raised at fair value. In short, the alleged manipulators created a vicious cycle: their trades drove the price down, which forced the company to issue more shares (driving price down further), all of which hampered NWBO’s ability to bring a breakthrough therapy to market.
Case Study: Biotech Breakthroughs Under Attack
The biotech sector offers some of the most dramatic examples of innovation being stalled by abusive short selling. These companies often depend on raising cash through equity to fund years of research and clinical trials. When shorts target them, the consequences can literally be life-or-death for the company and its potential patients.
Consider Northwest Biotherapeutics again. An academic analysis of NWBO’s saga noted how coordinated short selling and algorithmic high-frequency trading “nearly derailed a promising brain cancer vaccine” in development. Starting around 2013, NWBO became the target of a “wolfpack” of hedge funds, as described by one financial analyst following the stock. According to his investigation, a core group of funds worked in concert to attack NWBO and similar emerging biotech. Their playbook was brazen: induce sympathetic bloggers and commentators to publish slanted pieces “attacking and putting a negative spin on every aspect of the targeted company,” often accusing management of fraud or hype. Whenever NWBO issued good news, say, an encouraging trial result, the wolfpack would aggressively short the stock at the same time as negative blogs hit, ensuring that even positive developments looked bad as the share price plunged. In one instance in October 2015, NWBO’s stock inexplicably plummeted 30% in a single day on no news; observers noted “there is only one reasonable explanation for the decline and that was a coordinated short selling attack”. The ferocity was such that by 2015 the reported short position in NWBO exceeded the entire tradeable float of the company, implying extensive naked shorting (counterfeiting of shares) to sustain the assault. It has taken NWBO years of legal battles and scientific perseverance to survive this onslaught, and the fight isn’t over. Their experience lays bare how a few powerful short players can push an innovative biotech to the brink, delaying (or nearly denying) patients a novel treatment.
NWBO is not alone. Dozens of small biotech’s have reported similar bear raids. In some cases, the company doesn’t survive. A notorious example cited by advocates is Viragen, a Florida biotech that decades ago was working on a cutting-edge interferon therapy (an early form of immunotherapy). According to former insiders, Viragen’s stock was relentlessly naked short sold, tanking its share price and preventing it from raising the funds needed to continue R&D. The attack “destroyed their credit and ruined their future prospects” – Viragen ultimately fell into bankruptcy, and its experimental treatment never reached patients. Some in the scientific community lament that this set back cancer research by years, as Viragen’s therapy showed promise against diseases like metastatic melanoma and multiple sclerosis. While it’s hard to quantify how much potential was lost, the Viragen story is a cautionary tale of how manipulative short selling can snuff out a medical innovation before it ever gets a chance.
Regulators have slowly taken notice of these patterns. In one enforcement action, the SEC went after a Massachusetts hedge fund manager who shorted Ligand Pharmaceuticals (a biotech) and then disseminated false claims that the company was on the verge of bankruptcy. Over a matter of weeks, Ligand’s stock plunged more than 30%, until the fraud was exposed. This case underscores that “short and distort” schemes are not theoretical – they are happening, and they hurt real companies and investors. For every action the SEC catches, many others go unchecked, leaving biotech executives feeling vulnerable and spending precious time fighting rumors instead of curing diseases.
Clean Energy and Tech: Betting Against the Future
It’s not just biotech. Clean energy innovators and tech startups have increasingly found themselves in the crosshairs of short sellers employing similar tactics. Part of the problem is that many clean-tech ventures, solar, wind, electric vehicles, new battery technologies, often operate at a loss in early years, making them appear vulnerable. Large hedge funds have ramped up bets against green technology companies in recent times, with Bloomberg reporting that by late 2024, a majority of solar and EV stocks had more hedge funds holding short positions than long ones. In one sense, this reflects skepticism about these companies’ near-term prospects. But when short bets pile on too heavily, they can become a self-fulfilling prophecy: driving down share prices, spooking investors and lenders, and raising the cost of capital for climate solutions. It’s a headwind we can ill afford in the race to a sustainable economy.
Tesla, Inc. is perhaps the most high-profile example of a clean tech company weathering an onslaught of short selling. For years, Tesla was the most shorted stock on Wall Street, right as it was trying to revolutionize the auto industry with electric vehicles. CEO Elon Musk has often argued that the swarm of shorts nearly smothered Tesla in its infancy. “Short sellers are desperately pushing a narrative that will possibly result in Tesla’s destruction,” Musk told an interviewer in 2018. He described how detractors constantly spread rumors, claiming Tesla was on the brink of failure or that its technologies were fraudulent. “They’re constantly trying to make up false rumors and amplify any negative rumors… It’s really awful,” Musk said, characterizing some short sellers as “jerks who want us to die”. While Tesla ultimately overcame these bets against it, even to the point of turning the tables on short sellers with massive stock gains, the short-selling campaign forced Tesla to fight not just industrial challenges, but also a concerted PR and market manipulation battle. One veteran clean-energy investor noted the moral dilemma: “You can short Snapchat or Facebook all you want. Tesla’s mission is to address climate change – betting on its failure means betting against solutions for our children’s future”. This sentiment captures why piling on innovative clean-tech firms is viewed by some as not just a financial wager, but a societal risk.
Beyond Tesla, numerous smaller tech and infrastructure-oriented companies have faced similar attacks. Short sellers have targeted emerging battery tech companies and even nascent quantum computing firms with aggressive reports. In 2025, a short fund released a 183-page broadside against IonQ, a U.S. quantum computing startup, bluntly labeling it “a hoax” and alleging its breakthroughs were fake. IonQ’s stock promptly fell about 10% on the report’s release. The same short fund has repeatedly gone after other innovators – from a synthetic biology unicorn called Ginkgo Bioworks (which it called a “colossal scam”) to EV battery makers. Each time, the pattern is similar: publish a voluminous hit piece questioning the company’s technology and integrity, spark a sharp selloff, and leave the target scrambling to refute allegations. Even if the claims are eventually disproven, the damage to the company’s reputation and share price can take years to repair – precious time lost in fast-moving tech fields. Some startups never recover, either because funding dries up or because the public narrative turns so negative that talent and customers become wary. In effect, these short-selling tactics can suffocate promising ventures in the crib, denying society the benefits of their innovations.
Manipulating Perception and Reality
A common thread through these case studies is how market manipulation intersects with media manipulation. The short sellers’ “invisible hand” doesn’t just dump shares – it also shapes public perception of a company. Through anonymous blog posts, social media sockpuppets, biased research notes, or even coordinated mainstream media pieces, a narrative can be crafted that a company is overhyped, mismanaged, or on the verge of collapse. In the digital age, such narratives spread quickly and can be particularly persuasive to general investors who don’t have the time to dig into complex scientific or technical details. Critics say that unscrupulous shorts exploit this, knowing that fear can outrun fact. As The Los Angeles Times reported, algorithmic trading bots now scan platforms like Twitter and Reddit for sentiment; if false negative information is circulated by short-aligned sources, those algos can trigger real selling, amplifying the decline. Falsehoods, once out, can move markets before they can be corrected. That is why short-and-distort tactics are so dangerous – they intertwine with the psychology of the market. A bearish short report might cite “sources” or spurious data to sound authoritative, leaving the company to prove a negative (an often-impossible task) while its stock free-falls.
Even after a false rumor is debunked, confidence doesn’t fully return. For example, when one hedge fund manager loudly compared Tesla to Enron (implying fraud) in 2018, it grabbed headlines. Tesla’s fundamentals hadn’t changed, but the specter of “another Enron” hung in the air, chilling some investors until Tesla’s successes later proved the shorts wrong. The lingering doubt is exactly what manipulators bank on. It can manifest as a permanently suppressed valuation, a so-called “fraud discount, on companies that aren’t fraudulent but carry the scar of short seller accusations. This depresses the resources those companies can marshal for innovation. It’s essentially a tax on progress, siphoning value away from innovators to line the pockets of speculators betting against them.
None of this is to say that all short selling is evil or that every company targeted by shorts is a saint. Healthy skepticism has its place, and short sellers have at times uncovered real frauds (the early flags on Enron and Valeant Pharmaceuticals came from shorts). But the balance has tilted. When legitimate critique gives way to market manipulation and deceit, and when short selling becomes so excessive that it overshoots a reasonable assessment of a company’s flaws, it veers into destruction of value that didn’t need to be destroyed. In the words of one frustrated CEO, a company’s stock can become “a daily report card” hijacked by profiteers who don’t care if the grade is unfair. The result: promising startups are marked as failures in the market long before they have a chance to succeed.
Turning the Tide: Empowering Innovation and Fair Markets
It’s clear that abusive short selling tactics have created invisible headwinds for innovation – headwinds that merit far more attention and action. Restoring fairness will require stronger enforcement of existing rules (no more fake shares flooding the system), greater transparency (so that large short positions must be disclosed, as Nasdaq has advocated), and accountability for those who disseminate false information to crash stocks. Market participants and regulators alike are beginning to wake up – the SEC’s recent cases and proposals are a start – but meaningful change will also demand public pressure and awareness.
That’s where organizations like Fair Market Alliance step in. We are committed to shining sunlight on these shadowy practices, educating policymakers and the public on how Wall Street’s dirty tricks can stifle the next generation of innovators, and pushing for reforms that level the playing field for honest companies and investors. Every entrepreneur with a bold idea should compete on the merits of that idea – not against an unseen arsenal of manipulative trades and rumors.
You can help: join us in calling out market manipulation when you see it, demand better oversight from regulators, and support campaigns to modernize market rules. Follow Fair Market Alliance on social media and share this article with colleagues and friends. The more people understand this “innovation headwind,” the harder it becomes for it to remain in the shadows. By spreading awareness, we empower more investors to hold short sellers accountable and more innovators to persevere. Together, we can ensure that the only thing crushing our innovators’ dreams is the force of competition – not the invisible hand of deceit in the markets. Let’s tear down this headwind and let innovation soar.